Ascletis Pharma Inc.

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients
2022-05-11
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19
2022-04-19
Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland
2022-04-13
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
2022-04-10
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors
2022-04-06
Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province
2022-04-04
Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong
2022-04-03
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
2022-03-30
Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022
2022-03-27
Business Update on ASC10, an Oral Double Prodrug against COVID-19
2022-03-15

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1